Omentin-1 vs Plecanatide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Plecanatide (Plecanatide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Plecanatide |
|---|---|---|
| Category | Diabetes & Metabolic | Gastrointestinal |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Plecanatide |
| Molecular Weight | ~35 kDa | Approx. 1620 Da |
| Half-Life | hours | Local intestinal action; systemic half-life not clinically meaningful |
| Amino Acids | 313 | 16 |
| Typical Dose | No approved human dose; research use only | 3 mg once daily |
| Route | IV|SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 350 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Omentin-1 Dosing
not established|not established
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.